Nouscom (Group)

https://www.nouscom.com

Nouscom is a privately held oncology company developing next-generation immunotherapies. Nouscom's proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators. Nouscom is currently advancing clinical development of its lead program, NOUS-209, an off-the-shelf cancer vaccine based on shared frame shift neoantigens. The Company continues to develop its product candidate, NOUS-PEV, a personalized cancer neoantigen- vaccine, which is expected to enter clinical studies in 2020. Nouscom is led by an experienced management team with deep roots in the pharma and biotech industry (Merck, Novartis, Lilly, Incyte and Okairos (acquired by GSK)), and are veterans in the field of viral vectored genetic vaccines. Nouscom, which was founded in 2015 and is headquartered in Basel, Switzerland with operations in Rome, Italy, is backed by international life sciences investors: 5AM, Abingworth, LSP (Life Sciences Partners) and Versant Ventures. *

	Start	2016-05-17 existent
	Industry	cancer vaccine
	Industry 2	drug development
	Person	Udier-Blagovic, Marina (Nouscom 202002– CEO joined 201609 as COO before Versant Ventures + Novartis + McKinsey)
	Person 2	Nicosia, Alfredo (NousCom 201605–201905 CEO at NousCom Srl + Co-Founder before Okairos RETIRED 5/19)

	Region	Basel BS
	Country	Switzerland
	Street	18 Bäumleingasse
	City	4051 Basel
	Tel	+41-61-201-1831
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: Nouscom AG. (2/26/20). "Press Release: Nouscom Strengthens Its Management Team. Marina Udier, PhD Appointed as Chief Executive Officer and Patricia Delaite, MD Appointed as Chief Medical Officer". Basel.

		Record changed: 2023-07-10